Show simple item record

dc.contributor.authorAndera, Ladislaven_US
dc.contributor.authorGabrielli, Brianen_US
dc.contributor.authorNeuzil, Jirien_US
dc.contributor.editorSluyser, M.en_US
dc.date.accessioned2017-04-05T00:23:26Z
dc.date.available2017-04-05T00:23:26Z
dc.date.issued2005en_US
dc.date.modified2009-12-22T07:46:40Z
dc.identifier.isbn1402033036en_US
dc.identifier.doi10.1007/1-4020-3302-8_12en_AU
dc.identifier.urihttp://hdl.handle.net/10072/27932
dc.description.abstractHistone deacetylas inhibitors (HDIs) are a novel prospective group of potential anti-cancer agents, some of them being tested in a clinical setting. The major mode of action of these compounds is inhibition of the cell cycle transition and, consequently, differential regulation of a number of genes necessary for cell proliferation, while favouring expression of genes rather associated with anti-proliferative pathways and with cell death signalling. This implies a possible role of HDIs in adjuvant treatment of tumours resistant to other agents, operating via a different molecular mechanism. The TNF-related apoptosis-inducing ligant (TRAIL) is a promising immunological inducer of apoptosis efficient against a variety of tumours with a remarkably selective mode of action. However, some malignancies are resistant to TRAIL treatment. In this paper, we review our current knowledge on HDI-mediated sensitisation of TRAIL-non-responsive tumours to this apoptogen and suggest a future clinical potential of HDIs and TRAIL in cancer management.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherSpringeren_US
dc.publisher.placeDordrechten_US
dc.relation.ispartofbooktitleApplication of apoptosis to cancer treatmenten_US
dc.relation.ispartofchapter12en_US
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom271en_US
dc.relation.ispartofpageto292en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchMulti-Disciplinaryen_US
dc.subject.fieldofresearchcode999999en_US
dc.titleHistone deacetylase inhibitors as a treatment of TRAIL-resistant cancersen_US
dc.typeBook chapteren_US
dc.type.descriptionB1 - Book Chapters (HERDC)en_US
dc.type.codeB - Book Chaptersen_US
gro.date.issued2005
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Book chapters
    Contains book chapters authored by Griffith authors.

Show simple item record